stockportfolio.pro
NeoGenomics, Inc. P/E Ratio 2010–2025
NeoGenomics, Inc. (NEO) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +5.7%/yr over 15 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | — | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | 208.50 | +130.4% |
| FY 2013 | 90.50 | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
Source: NeoGenomics, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for NeoGenomics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeNeoGenomics, Inc. — frequently asked questions
What is NeoGenomics, Inc.'s price-to-earnings ratio?
NeoGenomics, Inc. (NEO) reported price-to-earnings ratio of 208.50 for fiscal year 2014, per its SEC filings.
How has NeoGenomics, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2010 and 2025, NEO's price-to-earnings ratio grew at roughly 5.7% per year (compound annual rate), from 90.50 to 208.50.
Where does this data come from?
Figures are computed from NeoGenomics, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.